{"entity":{"type":"insider","cik":"0001280249","url":"/insider/0001280249","json_url":"/insider/0001280249.json","name":"TURNER DANIEL K III","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":25,"n_filings":12,"first":"2008-12-05","last":"2012-02-06","span_basis":"filed_date"},"name_variants":[{"name":"TURNER DANIEL K III","source":"filing","n_filings":12,"first_seen":"2008-12-05","last_seen":"2012-02-06"}],"transactions":[{"id":2942105,"accession":"0001104659-12-007036","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-12-007036","line_url":"/filing/0001104659-12-007036","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":57204.0,"shares_display":"57,204","price_per_share":1.45,"price_display":"1.45","price_state":"stated","total_value":82945.8,"total_display":"82,945.80","total_whole":"82,946","shares_owned_after":377958.0,"shares_owned_after_display":"377,958","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-22","filed_date":"2012-02-06","scope":"insider","n_lines":2},{"id":8955109,"accession":"0001181431-11-020717","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-11-020717","line_url":"/filing/0001181431-11-020717","is_derivative":false,"issuer_cik":"0001178711","issuer_name":"Transcept Pharmaceuticals Inc","issuer_ticker":"TSPT","issuer_name_source":null,"issuer_url":"/issuer/0001178711","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":130000.0,"shares_display":"130,000","price_per_share":8.1683,"price_display":"8.17","price_state":"stated","total_value":1061879.0,"total_display":"1,061,879.00","total_whole":"1,061,879","shares_owned_after":569361.0,"shares_owned_after_display":"569,361","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-03-29","filed_date":"2011-03-30","scope":"insider","n_lines":2},{"id":7236457,"accession":"0001104659-10-064215","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-10-064215","line_url":"/filing/0001104659-10-064215#line-2","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48057.0,"shares_display":"48,057","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":498712.0,"shares_owned_after_display":"498,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-12-23","filed_date":"2010-12-23","scope":"insider"},{"id":7236455,"accession":"0001104659-10-064215","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-10-064215","line_url":"/filing/0001104659-10-064215#line-1","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51943.0,"shares_display":"51,943","price_per_share":8.25,"price_display":"8.25","price_state":"stated","total_value":428529.75,"total_display":"428,529.75","total_whole":"428,530","shares_owned_after":546769.0,"shares_owned_after_display":"546,769","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-12-22","filed_date":"2010-12-23","scope":"insider"},{"id":7317285,"accession":"0001104659-10-062651","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-10-062651","line_url":"/filing/0001104659-10-062651#line-2","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":266365.0,"shares_display":"266,365","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":598712.0,"shares_owned_after_display":"598,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-12-13","filed_date":"2010-12-14","scope":"insider"},{"id":7317283,"accession":"0001104659-10-062651","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-10-062651","line_url":"/filing/0001104659-10-062651#line-1","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":333635.0,"shares_display":"333,635","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":865077.0,"shares_owned_after_display":"865,077","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-12-10","filed_date":"2010-12-14","scope":"insider"},{"id":7133268,"accession":"0001104659-10-015701","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-10-015701","line_url":"/filing/0001104659-10-015701#line-1","is_derivative":false,"issuer_cik":"0001094330","issuer_name":"Somaxon Pharmaceuticals, Inc.","issuer_ticker":"SOMX","issuer_name_source":null,"issuer_url":"/issuer/0001094330","owner_cik":null,"owner_name":"MONTREUX EQUITY PARTNERS III SBIC L P; TURNER DANIEL K III; Montreux Equity Managment III SBIC; MONTREUX EQUITY MANAGEMENT II SBIC LLC; MONTREUX EQUITY PARTNERS II SBIC LP; PALEFSKY HOWARD D","owner_display_name":"MONTREUX EQUITY PARTNERS III SBIC L P","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500000.0,"shares_display":"1,500,000","price_per_share":6.3824,"price_display":"6.38","price_state":"stated","total_value":9573600.0,"total_display":"9,573,600.00","total_whole":"9,573,600","shares_owned_after":695505.0,"shares_owned_after_display":"695,505","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-03-18","filed_date":"2010-03-22","scope":"insider"},{"id":5837274,"accession":"0001104659-09-070458","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-09-070458","line_url":"/filing/0001104659-09-070458#line-1","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":7.55,"price_display":"7.55","price_state":"stated","total_value":755000.0,"total_display":"755,000.00","total_whole":"755,000","shares_owned_after":1198712.0,"shares_owned_after_display":"1,198,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-17","filed_date":"2009-12-17","scope":"insider"},{"id":6009520,"accession":"0001104659-09-055957","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-09-055957","line_url":"/filing/0001104659-09-055957#line-1","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":10.2182,"price_display":"10.22","price_state":"stated","total_value":1021820.0,"total_display":"1,021,820.00","total_whole":"1,021,820","shares_owned_after":1298712.0,"shares_owned_after_display":"1,298,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-22","filed_date":"2009-09-23","scope":"insider"},{"id":6040050,"accession":"0001104659-09-055203","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-09-055203","line_url":"/filing/0001104659-09-055203#line-1","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":9.28,"price_display":"9.28","price_state":"stated","total_value":928000.0,"total_display":"928,000.00","total_whole":"928,000","shares_owned_after":1398712.0,"shares_owned_after_display":"1,398,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-17","filed_date":"2009-09-18","scope":"insider"},{"id":5687228,"accession":"0001104659-09-054827","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-09-054827","line_url":"/filing/0001104659-09-054827#line-3","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40904.0,"shares_display":"40,904","price_per_share":8.925,"price_display":"8.92","price_state":"stated","total_value":365068.2,"total_display":"365,068.20","total_whole":"365,068","shares_owned_after":1498712.0,"shares_owned_after_display":"1,498,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-16","filed_date":"2009-09-16","scope":"insider"},{"id":5687227,"accession":"0001104659-09-054827","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-09-054827","line_url":"/filing/0001104659-09-054827#line-2","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":135701.0,"shares_display":"135,701","price_per_share":8.9632,"price_display":"8.96","price_state":"stated","total_value":1216315.2032,"total_display":"1,216,315.20","total_whole":"1,216,315","shares_owned_after":1539616.0,"shares_owned_after_display":"1,539,616","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-15","filed_date":"2009-09-16","scope":"insider"},{"id":5687226,"accession":"0001104659-09-054827","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-09-054827","line_url":"/filing/0001104659-09-054827#line-1","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23395.0,"shares_display":"23,395","price_per_share":9.0015,"price_display":"9.00","price_state":"stated","total_value":210590.0925,"total_display":"210,590.09","total_whole":"210,590","shares_owned_after":1675317.0,"shares_owned_after_display":"1,675,317","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-14","filed_date":"2009-09-16","scope":"insider"},{"id":5603398,"accession":"0001181431-09-043818","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-09-043818","line_url":"/filing/0001181431-09-043818","is_derivative":false,"issuer_cik":"0001178711","issuer_name":"Transcept Pharmaceuticals Inc","issuer_ticker":"TSPT","issuer_name_source":null,"issuer_url":"/issuer/0001178711","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10450.0,"shares_display":"10,450","price_per_share":12.59669043062201,"price_display":"12.60","price_state":"stated","total_value":131635.415,"total_display":"131,635.42","total_whole":"131,635","shares_owned_after":536749.0,"shares_owned_after_display":"536,749","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-11","filed_date":"2009-09-14","scope":"insider","n_lines":3},{"id":5821040,"accession":"0001181431-09-043561","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001181431-09-043561","line_url":"/filing/0001181431-09-043561","is_derivative":false,"issuer_cik":"0001178711","issuer_name":"Transcept Pharmaceuticals Inc","issuer_ticker":"TSPT","issuer_name_source":null,"issuer_url":"/issuer/0001178711","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30574.0,"shares_display":"30,574","price_per_share":13.00558644599987,"price_display":"13.01","price_state":"stated","total_value":397632.8,"total_display":"397,632.80","total_whole":"397,633","shares_owned_after":638861.0,"shares_owned_after_display":"638,861","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-10","filed_date":"2009-09-11","scope":"insider","n_lines":3},{"id":5821034,"accession":"0001181431-09-043561","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-09-043561","line_url":"/filing/0001181431-09-043561","is_derivative":false,"issuer_cik":"0001178711","issuer_name":"Transcept Pharmaceuticals Inc","issuer_ticker":"TSPT","issuer_name_source":null,"issuer_url":"/issuer/0001178711","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35030.0,"shares_display":"35,030","price_per_share":13.135795032829003,"price_display":"13.14","price_state":"stated","total_value":460146.9,"total_display":"460,146.90","total_whole":"460,147","shares_owned_after":652861.0,"shares_owned_after_display":"652,861","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-09","filed_date":"2009-09-11","scope":"insider","n_lines":3},{"id":3830106,"accession":"0001181431-08-065860","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-08-065860","line_url":"/filing/0001181431-08-065860#line-1","is_derivative":false,"issuer_cik":"0001280249","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001280249","owner_cik":"0001280249","owner_name":"TURNER DANIEL K III","owner_display_name":"TURNER DANIEL K III","owner_url":"/insider/0001280249","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":3.4615,"price_display":"3.46","price_state":"stated","total_value":1038450.0,"total_display":"1,038,450.00","total_whole":"1,038,450","shares_owned_after":1698712.0,"shares_owned_after_display":"1,698,712","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-12-05","filed_date":"2008-12-05","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":24,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":21,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":24},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001382911","name":"Orexigen Therapeutics, Inc.","url":"/issuer/0001382911","role":"Director","n_filings":8,"first_seen":"2008-12-05","last_seen":"2012-02-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001178711","name":"Transcept Pharmaceuticals Inc","url":"/issuer/0001178711","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2009-09-11","last_seen":"2011-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001339455","name":"Somaxon Pharmaceuticals, Inc.","url":"/issuer/0001339455","role":"Ten percent owner","n_filings":1,"first_seen":"2010-03-22","last_seen":"2010-03-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001280249","retrieved_at":"2026-08-24T23:53:03+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}